期刊
CHEMICO-BIOLOGICAL INTERACTIONS
卷 254, 期 -, 页码 11-23出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.cbi.2016.05.001
关键词
Acetylcholinesterase; Butyrylcholinesterase; Alzheimer's disease; Coumarin; Benzopyrone; Enzyme inhibition
资金
- Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
The first report in literature of the isolation of coumarin was in the year 1820. After this report, other papers were published demonstrating the isolation and synthesis of coumarin and analogues. These compounds have been studying along the years for several different pathologies. One of these pathologies was Alzheimer's disease (AD), being the main cause of dementia in the contemporary world. There are two hypotheses to explain the pathogenesis mechanism and disease symptoms, then having the amyloid hypothesis and the cholinergic hypothesis. Some drugs for AD are based on the theory of cholinergic hypothesis, which objective is to increase the concentration of ACh in the synaptic cleft by the inhibition of cholinesterases. Over the last twenty years, many studies with coumarins compounds were reported as cholinesterases inhibitors. The aim of the present review is to discuss the studies and development of new compounds for AD treatment. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据